Chief Medical Officer · SUTRO BIOPHARMA, INC. (STRO)

Anne Borgman

FY2023 is the first fiscal year CompBrief holds for Anne Borgman as a named executive officer of SUTRO BIOPHARMA; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,335,549

Salary $418,982Stock awards $810,000Bonus $250,000

1st of 5 named executive officers at Sutro Biopharma by FY2023 total.

5 named officers on file for SUTRO BIOPHARMA, FY2023

Anne Borgman’s pay file — $29

  • 1 fiscal year of pay, line by line
  • STRO’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how SUTRO BIOPHARMA’s whole pay program stands against its peers

  • SUTRO BIOPHARMA’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on STRO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Anne Borgman’s full pay file as a PDF — free

More than this page: up to 10 years of Anne’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Anne Borgman compensation by year

SUTRO BIOPHARMA Summary Compensation Table · the one fiscal year held
In US dollars, as SUTRO BIOPHARMA reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$418,982
Bonus$250,000
Stock awards$810,000
Option awards$676,568
Non-equity incentive$180,000
Pension and deferred compensation$0
Total$2,335,549

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: SUTRO BIOPHARMA, INC. DEF 14A filed April 26, 2024, accession 0000950170-24-049207, and prior-year filings.

How this page was built: the SUTRO BIOPHARMA, INC. filed document, accession 0000950170-24-049207. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU150,000$643,500—
Option175,000—$5.40

Per the Outstanding Equity Awards at Fiscal Year-End table in SUTRO BIOPHARMA, INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

SUTRO BIOPHARMA’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Anne Borgman · this pageChief Medical Officer$2,335,549
William NewellChief Executive Officer$2,129,979
Hans-Peter GerberChief Scientific Officer$1,626,976
R.Ph. Jane ChungPresident and Chief Operating Officer$1,497,121
Edward AlbiniChief Financial Officer$1,018,488

The full SUTRO BIOPHARMA compensation record

free company brief

This page is one person within SUTRO BIOPHARMA's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the SUTRO BIOPHARMA proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are SUTRO BIOPHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anne Borgman's compensation dossier · One-time report. No refunds.